CTMX Tingkat bathi reged CytomX Therapeutics Inc

Simbol resmi perusahaan CytomX Corp (CTMX)

CytomX Therapeutics (CTMX) develops B2B solutions for the oncology market using tumor-activated drug technology. Innovative "smart" antibodies minimize therapy toxicity for healthy tissues. Robust patent protection and strict FDA regulations create a strong barrier to entry for competitors. The gross margin coefficient confirms these fundamental trends, with the metric currently standing at 91.30.

CytomX Therapeutics, Inc. (CTMX): Rentabilitas reged saka 04.07.2022 nganti 20.11.2026

Rincian metrik komprehensif lan analitis CytomX Pharma (CTMX)

- nilai saham lan prakiraan konsensus rega:
Ringkesan analisis perusahaan:CytomX Pharma - CTMX
Barang utama CytomX Therapeutics, Inc.

To objectively assess the operational efficiency of CytomX Therapeutics (CTMX), investors must analyze the company's ability to convert revenue into gross profit. The net gross margin trend reflects the share of income minus direct costs, which, in the context of licensing payments from BMS and Amgen, demonstrates the scalability of the Probody platform and the potential for long-term growth in return on equity.